Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Corundum is an international innovation group founded in 2014 by Yasushi Yamamoto. Headquartered in the United States, the organization operates with a mission to create synergies among researchers, investors, and innovators, aiming to foster life-changing discoveries that benefit humanity. Corundum has established four innovation hubs: Corundum Open Innovation (COI), Corundum Systems Biology (CSB), Corundum Neuroscience (CNS), and Corundum Convergence Institute (CCI). Each hub focuses on advancing personalized medicine and addressing critical challenges related to brain health and mental health.
As of now, Corundum manages a diverse portfolio of seven companies, emphasizing its commitment to the healthcare, biotech, and AI sectors. The organization engages in various activities, including venture investment, consulting services, sponsored research, and venture philanthropy. This multi-faceted approach allows Corundum to support groundbreaking research and development in key areas such as neuroscience and systems biology.
Corundum's unique structure as a convergence investment group enables it to operate across different domains, integrating scientific research with business strategies. This model not only enhances its investment capabilities but also positions Corundum as a significant player in the global healthcare innovation landscape.
Corundum invests primarily in the healthcare, biotech, and AI sectors, with a specific emphasis on neuroscience and systems biology. The organization targets early-stage investments, focusing on pre-seed, seed, seed+ (extension), and Series A funding rounds. Corundum's investment strategy is centered around advancing personalized medicine and addressing pressing health challenges, particularly those related to brain health and mental health.
The organization operates through its four innovation hubs, each specializing in different aspects of healthcare innovation. Corundum Open Innovation (COI) focuses on collaborative research, while Corundum Systems Biology (CSB) emphasizes microbiome research and multi-omics. Corundum Neuroscience (CNS) is dedicated to neurotechnology and brain science, and Corundum Convergence Institute (CCI) supports venture philanthropy and sponsored research initiatives.
Corundum seeks to partner with founders who demonstrate a strong commitment to scientific discovery and innovation. The organization values collaboration among its portfolio companies, leveraging its extensive network of researchers and innovators to drive impactful advancements in healthcare technology systems. Deal structures often include a combination of equity investments and strategic support, ensuring that portfolio companies receive the resources they need to succeed.
Corundum's portfolio consists of seven companies, each contributing to advancements in healthcare and technology. Notable investments include:
These companies exemplify Corundum's commitment to breakthroughs in neuroscience and systems biology. The organization actively collaborates with its portfolio companies to drive scientific discovery and innovation, ensuring that they are well-positioned to address critical health challenges.
Yasushi Yamamoto - Founder & CEO of Corundum. He graduated from Kyoto University with a degree in economics and began his career at Sumitomo Corporation. Under his leadership, Corundum has expanded its focus on convergence across science, technology, and business.
Liron Nunez Weismann - CEO of Corundum Neuroscience. She leads initiatives in neurotechnology and brain science, focusing on innovative solutions that enhance brain health. Her background includes extensive experience in venture capital and healthcare.
Jessica Schneider - Chief Scientific Officer of Corundum Systems Biology. She specializes in microbiome research and systems biology, driving advancements in understanding the human microbiome's impact on health. Jessica has a strong academic background and has contributed to numerous research publications in her field.
To pitch Corundum, founders should visit their website at corundum-corp.com. It is advisable to include a detailed pitch deck that outlines the business model, market opportunity, and team qualifications. Corundum prefers pitches that clearly articulate the problem being solved and the innovative approach taken.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are beneficial, as they can enhance the likelihood of a favorable review. Corundum values transparency and clarity in pitches, so providing comprehensive information upfront is crucial.
In March 2026, Corundum participated in the Series A funding round for Sequential, focusing on microbiome research. This investment highlights Corundum's commitment to advancing healthcare technology systems.
In November 2025, Corundum also invested in NextSense, which develops wearable EEG earbuds, participating in their Series A funding round. This investment underscores Corundum's focus on innovations in neuroscience and brain health.
Corundum continues to promote its innovation hubs, emphasizing their roles in fostering collaboration among researchers, investors, and innovators to drive impactful scientific advancements.
What are Corundum's investment criteria?
Corundum focuses on early-stage investments in healthcare, biotech, and AI sectors, particularly in neuroscience and systems biology. They seek companies that demonstrate innovative approaches to addressing health challenges.
How can I pitch to Corundum?
Founders can submit their pitches through Corundum's website at corundum-corp.com. It is recommended to include a clear overview of the business model, market potential, and team expertise in the pitch deck.
What makes Corundum different from other investors?
Corundum operates as a convergence investment group, integrating venture capital with sponsored research and venture philanthropy. This unique structure allows them to provide comprehensive support to portfolio companies.
What is Corundum's geographic focus?
While Corundum is based in the United States, it operates globally, with a particular emphasis on innovation hubs in Japan, Luxembourg, and Israel.
What kind of support do portfolio companies receive?
Corundum provides strategic support in research and development, access to a network of innovators, and expertise in venture philanthropy, fostering collaboration among portfolio companies.
What is the typical check size for investments?
Corundum invests in early-stage rounds, with check sizes varying based on the specific needs of the company and the stage of investment, typically ranging from pre-seed to Series A funding.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.